GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 70.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 149,945 shares of the company's stock after buying an additional 61,924 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC's holdings in GoodRx were worth $697,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. increased its holdings in shares of GoodRx by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 8,373,039 shares of the company's stock worth $38,935,000 after purchasing an additional 460,753 shares during the last quarter. Dimensional Fund Advisors LP raised its position in GoodRx by 22.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,992,311 shares of the company's stock valued at $9,264,000 after purchasing an additional 369,553 shares during the period. Clearbridge Investments LLC purchased a new position in GoodRx during the fourth quarter worth $5,863,000. Connor Clark & Lunn Investment Management Ltd. increased its position in GoodRx by 38.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company's stock valued at $5,714,000 after acquiring an additional 342,781 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in shares of GoodRx by 9.1% in the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock valued at $4,986,000 after acquiring an additional 89,032 shares during the period. Institutional investors own 63.77% of the company's stock.

Insiders Place Their Bets

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Friday, June 6th. The shares were sold at an average price of $4.09, for a total transaction of $43,668.93. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.53% of the company's stock.

GoodRx Stock Performance

Shares of NASDAQ GDRX traded down $0.05 during trading on Thursday, reaching $4.48. 1,394,918 shares of the company traded hands, compared to its average volume of 1,388,318. GoodRx Holdings, Inc. has a 12-month low of $3.68 and a 12-month high of $9.26. The stock has a market cap of $1.60 billion, a P/E ratio of -149.33, a PEG ratio of 2.46 and a beta of 1.16. The firm's fifty day simple moving average is $4.25 and its 200 day simple moving average is $4.53. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.04 by $0.05. GoodRx had a negative net margin of 2.05% and a positive return on equity of 5.35%. The business had revenue of $202.97 million for the quarter, compared to analyst estimates of $202.25 million. During the same quarter last year, the business earned $0.08 earnings per share. The company's revenue for the quarter was up 2.6% compared to the same quarter last year. As a group, research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on GDRX shares. The Goldman Sachs Group dropped their price target on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research note on Friday, May 9th. UBS Group reduced their price target on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating on the stock in a research note on Tuesday, May 13th. Wells Fargo & Company decreased their price target on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research note on Tuesday, April 29th. Finally, Truist Financial cut their price target on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a research note on Thursday, April 10th. Five research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $6.55.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.